5-Fluorocytosine, an antifungal agent with potential value as a chemotherapeutic agent, is being evaluated in the treatment of human cryptococcosis. In vitro studies with this agent have been hindered by the fact that it is inhibited significantly in the presence of partially degraded biological substances. This loss of activity is presumed to result from a competitive inhibition between the agent and its natural analogues. Procedures are described for in vitro studies with 5-fluorocytosine. These include methods for susceptibility testing and a bioassay for 5-fluorocytosine in biological fluids. Minimal inhibitory and minimal fungicidal concentrations of 5-fluorocytosine for Cryptococcus neoformans were usually in the range of 0.46 to 3.9 jsg/ml and 3.9 to 15.6 Ag/ml, respectively. Corresponding values for Candida albicans were 0.46 to 3.9,gg/ml and 15.6,gg/ml or greater, respectively. Strains of C. neoformans and C. albicans resistant to greater than 1,000 g/ml were encountered both after exposure to the drug and in the absence of any known exposure. Bioassays of specimens from patients treated with 5-fluorocytosine indicated that serum and cerebrospinal fluid concentrations of 10 to 30,jg/ml and 8 to 20,gg/ml, respectively were readily achieved with a dosage of 100 mg per kg per day. (1) is a fluoro-pyrimidine with distinct antifungal properties. It is active both in vitro and in vivo against such mycotic or opportunistic pathogens as Cryptococcus neoformans, Candida albicans, and Aspergillus fumigatus. It has no significant activity against other pathogens such as Histoplasma capsulatum or Blastomyces dermatitides. Currently, it is being evaluated in the treatment of human pulmonary and meningeal cryptococcosis (J. P. Utz et al., Antimicrob. Agents Chemother.-1968, in press) and also has been studied in a limited number of other human fungal infections including aspergillosis and candidiasis.
5-Fluorocytosine
In vitro susceptibility studies have shown 5-fluorocytosine to be distinctly less active than amphotericin B against C. neoformans (S. Shadomy et al., Antimicrob. Agents Chemother.-1968, in press ). This lesser degree of in vitro activity was found to be offset, however, by the demonstration of clinically significant concentrations of 5-fluorocytosine in sera and cerebrospinal fluids of patients receiving 100 mg per kg per day of the drug (S. Shadomy et al., Antimicrob. Agents Chemother.-1968, in press). In vitro studies have also demonstrated a significant loss of measurable antifungal activity when 5-fluorocytosine was tested in media containing partially degraded biological materials, such as commercial peptones, yeast extracts, or protein digests.
This report describes several procedures developed during the course of clinical and experimental studies with 5-fluorocytosine. These include methods for determinations of susceptibilities of fungal isolates to 5-fluorocytosine either in fluid or on solid media and a bioassay for measuring 5-fluorocytosine levels in sera, cerebrospinal fluids, or other biological fluids. The intent of this report is to communicate these procedures to other investigators interested in conducting clinical or laboratory investigations with this new and promising antifungal agent.
MATERIALS AND METHODS
Media. Previous studies with 5-fluorocytosine revealed that maximum activity of this drug can be demonstrated only in a completely synthetic medium (S. Shadomy et al., Antimicrob. Agents Chemother.-1968, in press ). The basic medium selected for all studies with this agent was Yeast Nitrogen Base (YNB; Difco) supplemented with L-asparagine and dextrose. This medium was prepared in the following way. A 6.7-g amount of YNB was dissolved together with 1.5 g of L-asparagine and 10.0 g of dextrose in 100 ml of distilled water. The resulting solution, which was sterilized by filtration, provided a 1OX concentrate which was further diluted 1:10 either in sterile water (for YNB broth) or in melted sterile 2% plain agar (for YNB agar), as required for the particular test being performed.
Solutions of 5-fluorocytosine. Stock solutions of 5-fluorocytosine (Hoffman-La Roche, RO 2-9915) were APPL. MICROBIOL. prepared in normal saline, pH 6.5, and were sterilized by filtration. A concentration of 10,000 ptg/ml provided a solution suitable, after appropriate dilutions, for all laboratory studies. The stock solutions should be stored at -40 C in individual portions.
In vitro susceptibility testing in liquid media. This procedure is suitable for susceptibility studies with yeast-like species such as C. albicans and C. neoformans. Cultures of the organisms to be tested should be maintained on an antibiotic-free medium such as Sabouraud agar. Inocula for testing were prepared from fresh cultures grown at 30 or 37 C in YNB broth. The mature broth cultures were diluted in sterile YNB broth and were adjusted to a light transmission at 530 nm of approximately 95%. The adjusted inocula contained approximately 105 cells per ml.
Twofold serial dilutions of 5-fluorocytosine, extending from 1,000 to 0.12 pg/ml, were prepared in 1.0-ml volumes in sterile YNB broth. The tubes of diluted drug in YNB broth were then inoculated with 0.05 ml of the adjusted inocula and incubated at either 30 or 37 C for 48 hr. Controls employed with this procedure included a drug-free tube of YNB broth for each organism being tested and a series of 5-fluorocytosine dilutions in YNB broth inoculated with Saccharomyces cerevisiae ATCC 9763. Cultures and inocula of S. cerevisiae were prepared in YNEB broth in exactly the same fashion as the test organisms.
When large numbers of organisms were being tested, an alternate procedure for preparing the dilutions of 5-fluorocytosine in YNB broth was used. In this procedure, 10-fold higher dilutions of the drug, starting at 5,000 pg/ml, were first prepared in lOX YNB concentrate, then individually diluted 1:10 in sterile water, and finally dispensed in 1.0-ml volumes. The 1,000 p&g/ml concentration of 5-fluorocytosine was prepared by diluting the 10,000 p&g/ml solution of the drug directly into YNB broth.
After incubation, the tubes were examined, by use of a magnifying agglutination viewer (Clay-Adams, A-2330) Twofold serial dilutions of 5-fluorocytosine, extending from 1,000 to 0.50 pug/ml, were prepared in lOX YNB concentrate. These solutions were then diluted 1:10 in melted, sterile 2% plain agar, with 5.0-mi volumes of each final dilution being dispensed into sterile, screw-cap test tubes. The tubes were then slanted. Three tubes of diluted drug in agar were required at each concentration of drug for each strain being tested. Growth-control tubes were prepared by diluting drug-free YNB concentrate 1:10 in melted, sterile 2% plain agar; three growth control tubes were required for each strain being tested. The final concentrations of 5-fluorocytosine in YNB agar ranged from 100 to 0.05 ,g/ml. After hardening in a slanted position, the tubes were then inoculated with 0.05 ml each of the prepared suspensions of the organisms being tested. As a control, a similar series of tubes with various concentrations of 5-fluorocytosine were inoculated with 0.05 ml each of a fresh suspension of S. cerevisiae ATCC 9763, prepared in the same manner as employed for susceptibility testing in broth.
The inoculated tubes were incubated at either 30 or 37 C until adequate growth appeared in the drug-free growth control tubes. The 5-fluorocytosine-containing tubes were then examined to determine the MIC. This value is defined as the lowest concentration of drug which inhibits growth in the central portions in all three tubes. Levels of partial inhibition were also recorded if observed. Partially inhibited growth occurring on the thinner periphery of the upper portion of the slanted media was usually ignored in recording the results of this test.
Determination of concentrations of 5-fluorocytosine in sera or other biological fluids. This cylinder plate bioassay procedure is suitable for measuring concentrations of 5-fluorocytosine in sera, urines, cerebrospinal fluids, or tissue homogenates. S. cerevisiae ATCC 9763 was used as the indicator organism. The lower limit of sensitivity was in the range of 0.4 to 0.5 gg/ml.
Plates used in the bioassay were prepared by adding 0.2 ml of an adjusted suspension of S. cerevisiae to 100 ml of melted sterile YNB agar held at a temperature of 52 C, and then dispensing the seeded agar in 10 ml volumes into sterile, glass petri dishes (22 by 100 mm). The suspension of S. cerevisiae was prepared from a fresh, 72-hr-old culture grown in sterile YNB broth which was harvested and adjusted to a light transmission of 65 to 70% as measured at 530 nm. Pressed petri dishes (Pyrex improved form) were preferred to standard molded dishes because of more uniform internal dimensions. Several suitable methods for dispensing the seeded agar included wide-bore serological pipettes, fixed-volume tilting dispensers, and automatic self-filling syringes.
Dilutions of 5-fluorocytosine to be used in establishing the dose-response curve were prepared as follows. A sterile 10,000 pg/ml solution of 5-fluorocytosine was first diluted 1 :100 in normal saline and then 1:10 in pooled, normal human serum to give a stock solution containing 10 pg/ml. This solution was then mixed in appropriate proportions with normal serum to give solutions with the following concentrations: 0.2, 0.4, 0.6, 0.8, 1.0, and 1.2 pug/ml. A minimum vol-872 SHADOMY on October 26, 2017 by guest http://aem.asm.org/ Downloaded from ume of 1.0 ml was required for all solutions except that containing 0.8 sug/ml; 10 ml of the latter solution was required.
Twenty-one plates of seeded YNB agar were required for the dose-response curve. Three sterile, stainless-steel antibiotic assay cylinders were placed equidistantly apart on each plate. Two cylinders on each plate received 0.01 ml of a graded solution of 5-fluorocytosine in serum and the third received 0.01 ml of the 0.8 gg/ml solution. Three plates were prepared with each concentration of 5-fluorocytosine, and an additional one to three plates were prepared with drug-free serum.
Three plates of seeded YNB agar, each with three sterile assay cylinders, were required for each specimen being assayed. On each plate, 0.01-ml volumes of the unknown specimen were introduced into each of two assay cylinders and 0.01 ml of the 0.8 jug/ml solution of 5-fluorocytosine was introduced into the third cylinder. Unknown specimens usually require dilution in normal serum before assay as the anticipated levels, 10 to 30 Ag/ml, cannot be accommodated on the doseresponse curve. The dilution required is best determined by preliminary tests with a procedure for measuring serum inhibitory concentrations. The approximate concentration of 5-fluorocytosine in the assayed material should not exceed 2.0 ,ug/ml.
The plates prepared for determination of the doseresponse curve and for assay of unknown specimens were inspected for trapped air bubbles in the cylinders; these were removed by teasing with a hot needle. The plates were then covered with sterile, absorbant drying pads fitted in solid tops and were incubated at 37 C for 48 hr.
Zones of inhibition produced around the cylinders by the graded concentrations of 5-fluorocytosine were measured with either a metric caliper-type micrometer or the Fisher-Lilly zone reader (Fisher 7-906V2). One measurement was made for each zone. Similarly, two measurements were taken approximately 1800 apart for the zones produced around cylinders loaded with the 0.8 ;&g/ml solution. These latter measurements are used to calculate a standard reference-point correction value which is used for correction of measurements obtained for both the dose-response curve and unknown specimens.
Separate determination was made of the average value of the two measurements obtained for the zone produced by the 0.8 ;&g/ml or reference-point solution of 5-fluorocytosine and the two zones produced by the graded concentrations of 5-fluorocytosine for each plate prepared for the dose-response curve. The overall average of all of the average reference-point values was then determined. This average was the standard reference-point correction value. The individual average values obtained for each plate prepared with the graded concentrations of 5-fluorocytosine were then corrected as follows. The average reference-point value obtained for a particular plate was compared with the standard reference-point correction value. If the two values were identical, the average of the two measurements obtained for the graded solution of 5-fluorocytosine was used without correction. If the standard reference-point value was higher than the individualplate, reference-point value, then the difference in the two values was added to the average obtained from the measurements of the two zones produced by the graded solution of 5-fluorocytosine. If the standard reference-point value was smaller, then the difference between the two readings was subtracted from the average of the measurements for the graded solution of 5-fluorocytosine. The three corrected values obtained for each concentration of 5-fluorocytosine were then averaged, and the final values were plotted on semilogarithmic paper, with concentration of drug in micrograms per milliliter as the ordinate and zones of inhibition in millimeters as the abscissa. The slope of the dose-response curve was determined by calculation by inspection.
The zones of inhibition produced on plates prepared with unknown specimens were measured in a fashion identical to the above. Two measurements were obtained for the zone produced by the reference-point preparation, and one was obtained for each of the two zones produced by the unknown specimen on each plate. The average values for these measurements were determined for each plate, and the standard referencepoint correction value was applied as before. The corrected values for each of the three plates prepared for an unknown specimen were then averaged, and this final value was applied to the dose-response curve to determine the concentration, in micrograms per milliliter, of measurable 5-fluorocytosine in the original or diluted unknown specimen.
RESULTS
In vitro susceptibility testing in liquid media. The effect of the composition of liquid media on the results of susceptibility determinations with 5-fluorocytosine against test strains of C. neoformans are shown in Table 1 . The procedures used in these determinations have been published elsewhere (S. Shadomy et al., Antimicrob. Agents Chemother.-1968, in press). When tested in a complex medium such as yeast-beef broth, which contains a variety of extracts and peptones, 5-fluorocytosine appeared to be inactive. However, when tested in a less complex medium such as Casamino Acids broth, both fungistatic and fungicidal activities were demonstrable. Maximum antifungal activity was best measured in a synthetic medium free from any preformed biological substances. In YNB broth, the medium adopted for in vitro studies with 5-fluorocytosine, MIC values of this agent against C. neoformans usually were in the range of 0.46 to 3.9 gg/ml, with corresponding MFC levels of from 1.85 to 15.6 ,ug/ml. Similar levels of fungistatic activity were measured when 5-fluorocytosine was tested in normal serum; however, fungicidal activity was reduced by as much as fivefold in the presence of serum.
When 5-fluorocytosine was tested in YNB broth against clinical isolates of C. neoformans, the results were in general agreement with those bPatient R. B., isolated from resected heart valve after treatment with 5-fluorocytosine.
treated for cryptococcal meningitis with 5-fluorocytosine also revealed a significant tendency for the emergence of strains of C. neoformans resistant to this agent. Such strains were generally resistant to more than 1,000 ,ug/ml (Table 2) . 5-Fluorocytosine was also active in vitro against C. albicans and is being studied, on a limited basis, in treatment of infections caused by this opportunistic pathogen. In vitro susceptibility data indicated that, although inhibitory levels of 5-fluorocytosine for C. albicans are similar to corresponding levels for C. neoformans, this drug is less active as a fungicidal agent against C. albicans (Table 3) . As in the case with C. neoformans, strains of C. albicans resistant to 5-fluorocytosine were encountered. One resistant strain for which data are given here, 1495, was isolated from a case of endocarditis, caused by C. albicans, after several weeks of treatment with 5-fluorocytosine.
Unfortunately, pretreatment cultures were not available in this case, and it is not known whether this strain was originally susceptible to the drug. The two other resistant strains were tested before any known exposure to the drug.
Temperature of incubation appeared to have a definite effect on the results of in vitro testing with 5-fluorocytosine. Generally, MIC and MFC values were somewhat lower when measured at 37 C than the corresponding values obtained at 30 C (Tables 2 and 3 ). Although this difference is not beyond the limits of experimental error, it is sufficient to warrant the use of one standard temperature of incubation for all testing with this drug. In this study, 37 C was selected as the standard temperature.
In vitro susceptibility testing on solid media. Data on the in vitro and in vivo antifungal properties of 5-fluorocytosine suggested that this agent may be active against such filamentous fungi as Aspergillus or Penicillin species. Accordingly, the following procedure for testing such activity was developed. Six test strains of A. fumigatus, including five study strains and one clinical isolate, were tested (Table 4 ). The antifungal activity of 5-fluorocytosine against A. fumigatus appeared to be somewhat limited. However, control data obtained with S. cerevisiae suggested that the results of susceptibility testing with 5-fluorocytosine in agar media inherently will be several fold higher than corresponding results obtained with 5-fluorocytosine prepared in liquid media. In this respect, it should be noted that, when measured in YNB broth, the MIC and MFC of 5-fluorocytosine for S. cerevisiae generally were in the range of 0.03 to 0.78 ,ug/ml, whereas when tested in YNB agar 5-fluorocytosine was partially inhibitory for S. cerevisiae at a concentration of 0.78 Aug/ml and completely inhibitory at 6.24 tig/ml. Thus, partial inhibition of four of the six strains of A. fumigatus by 5-fluorocytosine at a concentration of 50 or 100 ,g/ml is indicative of definite levels of antifungal activity and may reflect potential clinical usefulness of this agent in the treatment of human aspergillosis.
Determination of concentrations of 5-fluorocytosine in sera and cerebrospinal fluids. The doseresponse curve obtained for 5-fluorocytosine is linear and free from curvilinear deviation throughout its entire range. In a composite curve (Fig. 1) derived from five individual dose-response curves, the lower limit of sensitivity was 0.4 pig/ml; this same degree of sensitivity was obtained in three of the five curves represented in the composite curve. The large zones of inhibition, in excess of 30 mm, produced by 5-fluorocytosine in concentrations greater than 1.0 Ag/ml limited the upper region of the dose-response curve. However, freedom from curvilinear error permitted exten- Fig. 3. sion of the curve to concentrations as high as 3 or 4 jig/ml.
When saline rather than serum was used as the diluent, zones of inhibition for graded concentrations of 5-fluorocytosine were considerably larger and the lower limit of sensitivity of the bioassay was 0.20 ,gg/ml or less (Fig. 2) Tables 5 and 6 , and the dose-response curves are depicted in Fig. 3 . In the first series, performed on 6 November 1968 on specimens obtained from a patient receiving a dosage of 5-fluorocytosine of 100 mg per kg per day, concentrations of the drug in cerebrospinal fluids ranged from 8.5 to 15.5 ,g/ml and from 11 to 20 4ug/ml in sera. In the second series, performed on 13 Routine susceptibility testing with 5-fluorocytosine and C. neoformans or C. albicans can be performed satisfactorily in a synthetic medium such as YNB broth. In the case of C. neoformans, fungistatic and fungicidal concentrations will be in the range of 0.46 to 3.9 ,tg/ml and 3.9 to 15.6 ,ug/ml respectively. Corresponding values for C. albicans of 0.46 to 3.9 Ag/ml and 15.6,4g/ ml or greater can be anticipated. However, the natural occurrence or the emergence of resistant strains of either organism during therapy necessitates the inclusion of much higher drug concentrations with in vitro susceptibility testing procedures. Such strains, when they are encountered, have been found to be resistant to concentrations greater than 1,000 or 2,000 gg/ml. Experience with these resistant strains further suggests that susceptibility tests be performed routinely throughout the period of therapy with 5-fluorocytosine as long as positive cultures are recovered from clinical specimens. As an alternative to this, the inclusion of plates of YNB agar, supplemented with 100 ,ug or more of 5-fluorocytosine per ml in routine mycological isolation protocols, might be considered.
Results from susceptibility testing with 5-fluorocytosine in solid media suggest that such data do not provide a true measure of the antifungal activity of this agent. This is demonstrated in a comparison of results obtained for S. cerevisiae when tested in both liquid and solid media. When tested in YNB broth, 5-fluorocytosine is both fungistatic and fungicidal for S. cerevisiae at a concentration of less than 0.1 ,g/ ml. In contrast, fungistatic levels are in the range of 1 to 6.25 ,g/ml or more when tested in YNB agar.
The bioassay described here for 5-fluorocytosine is readily adaptable to a variety of materials. In addition to assay of sera and cerebrospinal fluids, it has also been used successfully to assay the 5-fluorocytosine content of such specimens as urine and tissue homogenates. The doseresponse curve for the bioassay is both highly reproducible and free from curvilinear deviation throughout its entire range. Thus, although the range of concentrations used to determine the dose-response curve is limited (0.4 to 1.2 ,ug/ml), the actual curve may be extended by simple inspection to include a much greater range of concentrations. However, such extension does not eliminate the requirement for dilution of most specimens before assay. The procedure now employed in our laboratories for bioassay of 5-fluorocytosine calls for the assay of both the original specimen and a 1:5 dilution of the specimen in normal human serum. The loss of activity by 5-fluorocytosine in the presence of serum, as demonstrated both in the differences between dose-response curves prepared in saline and those prepared in serum and also in the marked reduction of fungicidal activity when in vitro susceptibility tests are performed in serum, precludes the use of any other diluent. -1963, p. 566-568. 
